AKT1 and rhabdomyosarcoma: Over-activation of the PI3K-Akt pathway is one of the most frequently altered signal transduction pathways in rhabdomyosarcoma, affected in approximately 59% of ARMS and 29% of ERMS cases, making it a potential therapeutic target [52].